logo
GaldermaDeliversRecord2025ResultsWithNetSalesof5.207BillionUSD,up17.7%atConstantCurrency1,andCoreEBITDA2of1.211billionUSD,Growing18.9%atConstantCurrency
===2026/3/5 16:11:22===
ix more than offsetting pricing effects from the competitive environment. In the fourth quarter, net sales grew 25.2% year-on-year at constant currency, reflecting an acceleration in each product category.

Net sales growth for the year was widespread across geographies and product categories. Both geographies’ net sales grew double-digits while all product categories outpaced their respective markets.

International sustained its strong net sales growth momentum in highly attractive, largely underpenetrated markets. Injectable Aesthetics delivered double-digit net sales growth and outperformed the market in both Neuromodulators and Fillers & Biostimulators. Both Restylane and Sculptra delivered net sales growth with market share gains in most key countries despite continued softness in the Filler market. Dermatological Skincare also delivered double-digit net sales growth, with outstanding growth particularly in India and China. Therapeutic Dermatology net
=*=*=*=*=*=
当前为第5/55页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页